You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 10, 2025

CLINICAL TRIALS PROFILE FOR WARFARIN SODIUM


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Warfarin Sodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00203580 ↗ Trial of the Effect of Low-Molecular-Weight Heparin (LMWH) Versus Warfarin on Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (DVT) (Main LITE Study) Completed Canadian Institutes of Health Research (CIHR) Phase 4 1994-12-01 The purpose of this study is to assess the long-term treatment of patients with proximal venous thrombosis through the administration of subcutaneous low-molecular-weight heparin (tinzaparin sodium) versus the standard care use of intravenous heparin followed by oral warfarin sodium.
NCT00203580 ↗ Trial of the Effect of Low-Molecular-Weight Heparin (LMWH) Versus Warfarin on Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (DVT) (Main LITE Study) Completed Dupont Applied Biosciences Phase 4 1994-12-01 The purpose of this study is to assess the long-term treatment of patients with proximal venous thrombosis through the administration of subcutaneous low-molecular-weight heparin (tinzaparin sodium) versus the standard care use of intravenous heparin followed by oral warfarin sodium.
NCT00203580 ↗ Trial of the Effect of Low-Molecular-Weight Heparin (LMWH) Versus Warfarin on Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (DVT) (Main LITE Study) Completed LEO Pharma Phase 4 1994-12-01 The purpose of this study is to assess the long-term treatment of patients with proximal venous thrombosis through the administration of subcutaneous low-molecular-weight heparin (tinzaparin sodium) versus the standard care use of intravenous heparin followed by oral warfarin sodium.
NCT00203580 ↗ Trial of the Effect of Low-Molecular-Weight Heparin (LMWH) Versus Warfarin on Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (DVT) (Main LITE Study) Completed University of Calgary Phase 4 1994-12-01 The purpose of this study is to assess the long-term treatment of patients with proximal venous thrombosis through the administration of subcutaneous low-molecular-weight heparin (tinzaparin sodium) versus the standard care use of intravenous heparin followed by oral warfarin sodium.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Warfarin Sodium

Condition Name

Condition Name for Warfarin Sodium
Intervention Trials
Thrombosis 6
Venous Thrombosis 5
Healthy 4
Cirrhosis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Warfarin Sodium
Intervention Trials
Thrombosis 12
Venous Thrombosis 7
Fibrosis 5
Thromboembolism 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Warfarin Sodium

Trials by Country

Trials by Country for Warfarin Sodium
Location Trials
United States 69
Japan 13
China 7
Canada 6
Brazil 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Warfarin Sodium
Location Trials
Texas 4
Ohio 4
Utah 3
California 3
Maryland 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Warfarin Sodium

Clinical Trial Phase

Clinical Trial Phase for Warfarin Sodium
Clinical Trial Phase Trials
Phase 4 10
Phase 3 8
Phase 2/Phase 3 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Warfarin Sodium
Clinical Trial Phase Trials
Completed 19
Terminated 6
Unknown status 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Warfarin Sodium

Sponsor Name

Sponsor Name for Warfarin Sodium
Sponsor Trials
Boehringer Ingelheim 4
Yangzhou University 3
Dupont Applied Biosciences 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Warfarin Sodium
Sponsor Trials
Other 45
Industry 21
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Warfarin Sodium: Clinical Trials, Market Analysis, and Projections

Last updated: January 5, 2025

Introduction to Warfarin Sodium

Warfarin sodium, a widely used oral anticoagulant, has been a cornerstone in the prevention and treatment of thromboembolic disorders for decades. Its efficacy in preventing blood clots makes it a critical medication in managing conditions such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism.

Clinical Trials and Efficacy

Loading Doses and Anticoagulation Onset

A significant clinical trial compared the efficacy of 5-mg and 10-mg warfarin loading doses in achieving therapeutic international normalized ratio (INR) levels. The study found that a 5-mg loading dose was as effective as a 10-mg dose in achieving an INR between 2.0 and 3.0 on consecutive days, with fewer instances of overanticoagulation in the 5-mg group[1].

This trial highlighted that using a lower initial dose does not delay the attainment of therapeutic INR levels and may reduce the risk of early overanticoagulation and potential hypercoagulable states. This finding suggests that there may be no benefit to using higher loading doses of warfarin when initiating therapy.

Quality of Life and Long-term Therapy

Another study examined the impact of long-term warfarin therapy on quality of life. The results indicated that warfarin therapy does not significantly decrease perceived health unless a bleeding episode occurs. Patients on warfarin generally reported similar health perceptions to those in the control group, suggesting that the benefits of warfarin in preventing thromboembolic events may outweigh the potential negative effects on quality of life[4].

Market Analysis

Market Size and Growth

The global warfarin sodium market is projected to experience steady growth over the coming years. As of 2024, the market size was valued at approximately USD 197.69 billion and is expected to reach USD 283.3 billion by 2031, growing at a compound annual growth rate (CAGR) of 4.60% from 2024 to 2031[2].

Geographic Variations

The market is segmented geographically into North America, Europe, Asia Pacific, and the rest of the world. Europe is expected to be the fastest-growing market due to high awareness of conditions such as deep vein thrombosis and pulmonary embolism, for which warfarin is commonly prescribed. The Asia-Pacific region is also anticipated to grow as awareness and access to healthcare increase[2].

Application Segments

The market is further segmented by application into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies, which stock a wider range of medications, are expected to drive demand due to the specialized nature of warfarin therapy and the need for expert advice on its use[2].

Market Trends and Drivers

Cost-Effectiveness and Long-Term Usage

Warfarin remains a cost-effective solution for managing anticoagulation, particularly in low- and middle-income countries. Its long history and well-established methods of monitoring and dosage adjustments make it a reliable choice for many patients. These factors are expected to maintain its demand even as newer anticoagulants emerge[3].

Expanding Clinical Applications

Warfarin's role in treating additional conditions, such as deep vein thrombosis and pulmonary embolism, is likely to increase as new treatment protocols evolve. Clinical studies exploring its benefits in other cardiovascular conditions may also extend its usage into the future[3].

Population Growth and Aging

The global burden of cardiovascular diseases is rising, particularly among aging populations. This trend is expected to increase the demand for reliable anticoagulants like warfarin, especially in regions with limited access to newer therapies[3].

Competitive Landscape

Competition from Newer Anticoagulants

Warfarin faces competition from direct oral anticoagulants (DOACs), which have been gaining popularity due to their ease of use and reduced need for monitoring. However, warfarin's cost-effectiveness and established clinical profile ensure it remains a significant player in the anticoagulant market[3].

Generic Versions and Price Pressure

The availability of generic versions of warfarin is expected to reduce prices, making it even more accessible and further securing its market share in emerging economies. Geopolitical and healthcare policy shifts, such as drug price regulations and insurance coverage, could also impact warfarin's accessibility[3].

Future Projections

Market Growth and Stability

The warfarin sodium market is expected to experience stable yet steady growth from 2023 to 2033. Key drivers include the increasing global burden of cardiovascular diseases, the cost-effectiveness of warfarin, and its long-term usage and familiarity among patients and healthcare providers[3].

Emerging Markets and Awareness

The Asia-Pacific region, in particular, is predicted to grow as awareness of thromboembolic conditions increases. This growth will be driven by expanding healthcare access and the need for reliable and affordable anticoagulant therapies[2].

Key Takeaways

  • Clinical Efficacy: Warfarin sodium remains effective in achieving therapeutic INR levels, with lower loading doses potentially reducing overanticoagulation risks.
  • Market Growth: The global warfarin sodium market is projected to grow at a CAGR of 4.60% from 2024 to 2031.
  • Geographic Trends: Europe is the fastest-growing market, while the Asia-Pacific region is expected to grow due to increasing awareness and healthcare access.
  • Cost-Effectiveness: Warfarin's affordability and long-term usage ensure its continued relevance despite competition from newer anticoagulants.
  • Expanding Applications: Warfarin's role in treating various cardiovascular conditions is likely to expand, further securing its market position.

FAQs

What is the current market size of warfarin sodium, and what is its projected growth?

The current market size of warfarin sodium was valued at approximately USD 197.69 billion in 2024 and is projected to reach USD 283.3 billion by 2031, growing at a CAGR of 4.60% from 2024 to 2031[2].

How does the loading dose of warfarin affect its efficacy?

A clinical trial found that a 5-mg loading dose of warfarin is as effective as a 10-mg dose in achieving therapeutic INR levels, with fewer instances of overanticoagulation in the 5-mg group[1].

What are the key drivers of the warfarin sodium market?

Key drivers include the cost-effectiveness of warfarin, its long-term usage and familiarity, expanding clinical applications, and the increasing global burden of cardiovascular diseases[3].

How does warfarin sodium impact the quality of life of patients?

Long-term warfarin therapy does not significantly decrease perceived health unless a bleeding episode occurs. Patients generally report similar health perceptions to those in the control group[4].

What regions are expected to drive the growth of the warfarin sodium market?

Europe is expected to be the fastest-growing market, while the Asia-Pacific region is anticipated to grow due to increasing awareness and healthcare access[2].

Sources

  1. A Randomized Trial Comparing 5-mg and 10-mg Warfarin Loading Doses - JAMA Network
  2. Warfarin Sodium (CAS 129-06-6) Market Size, Forecast - Verified Market Research
  3. Warfarin Sodium Market Outlook and Growth Trends Overview - GitHub
  4. The Impact of Long-term Warfarin Therapy on Quality of Life - JAMA Network
  5. Warfarin Sodium Clathrate Market Size, Share, Development by 2025 - OpenPR

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.